RTH258

Racing Novartis on Eylea rival, the FDA trips up Regeneron at the finish line
Endpoints
Mon, 08/13/18 - 11:39 am
Regeneron
Eylea
Novartis
RTH258
wet age-related macular degeneration
FDA
Eyeing Eylea’s $5B sales, Novartis touts solid 12-week dosing data for its rival RTH258
Endpoints
Mon, 04/30/18 - 09:04 pm
Novartis
Regeneron
Eylea
RTH258
wet age-related macular degeneration
With Novartis closing in, Regeneron scraps Eylea combo drug in a major setback
Endpoints
Mon, 11/27/17 - 09:18 am
Novartis
Regeneron
Eylea
RTH258
nesvacumab
Bayer
Novartis spotlights its top 4 blockbuster late-stage pipeline projects
Endpoints
Mon, 11/13/17 - 09:35 am
Novartis
RTH258
wet age-related macular degeneration
AMG 334
migraines
Cosentyx
ACZ885
Novartis outlines its full case on why RTH258 can carve out a big piece of the AMD market held by Regeneron
Endpoints
Fri, 11/10/17 - 10:23 pm
Novartis
RTH258
wet age-related macular degeneration
Regeneron
Novartis trial results could spell trouble for Regeneron
Drug Delivery Business News
Wed, 06/21/17 - 07:33 pm
Novartis
Regeneron
clinical trials
RTH258
neovascular age-related macular degeneration
Novartis wins big in head-to-head Eylea matchup, setting up a looming market feud with Regeneron
Endpoints
Tue, 06/20/17 - 08:51 am
Novartis
Eylea
Regeneron
RTH258
Novartis treatment for vision loss meets goals in study
Yahoo/Reuters
Fri, 02/27/15 - 07:11 pm
Novartis
Alcon
RTH258
wet age-related macular degeneration